Glibenclamide partly reverses monensin inhibition of insulin secretion, in vivo

https://doi.org/10.1016/0024-3205(93)90448-CGet rights and content

Abstract

Glibenclamide, a second generation sulfonylurea, is an oral hypoglycemic drug. It seems to act mainly on the ATP-driven K+ - channels of the β-cells of pancreas determining insulin secretion. Because monensin, a Na+/H+ antiport, is able when administered to rats invivo to inhibit insulin secretion, the action of glibenclamide is studied on glycemia and insulinemia to verify if it can antagonize the action of monensin. The results show that glibenclamide is able to partly reverse ionophore induced hyperglycemia and the inhibition of insulin secretion. These results might be interpreted as if glibenclamide only reverses the ATP-driven K+ - channel dependent insulin secretion. Moreover the antagonist action of glibenclamide is slightly delayed when both drugs are administered together. The role of Na+/H+ antiport in basal insulin secretion is discussed.

References (24)

  • H. Schmid-Antomarchi et al.

    J. Biol. Chem.

    (1987)
  • K.L. Gaines et al.

    J. Biol. Chem.

    (1988)
  • W.J. Malaisse et al.

    Biochim. Biophys. Acta.

    (1987)
  • H. Mollenhauer et al.

    Biochim. Biophys. Acta.

    (1990)
  • A.M. Tartakoff

    Cell

    (1983)
  • P.W. Ledger et al.

    Trends. Biochem. Sci.

    (1984)
  • L. Orci et al.

    Cell

    (1987)
  • L. Ali et al.

    Biochem. Biophys. Res. Commun.

    (1989)
  • S. Grinstein et al.

    Biochim. Biophys. Acta

    (1989)
  • A. Casu et al.

    Life Sciences

    (1992)
  • T.Y. Nelson et al.

    J. Biol. Chem.

    (1987)
  • L. Aguilar-Bryan et al.

    J. Biol. Chem.

    (1992)
  • View full text